Indevus Sanctura XR To Begin Phase III Trials “Shortly”
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm targets second half of 2006 for NDA submission for the extended-release formulation of the overactive bladder treatment. Sanctura maintains 3% share of new prescriptions in the quarter despite heavy promotion from competitors.